SynopsisEluxadoline is a novel, orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). The global Eluxadoline Reagent market was valued at US$ million in 2023 and is.....
SynopsisEluxadoline is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). The global Eluxadoline API market was valued at US$ million in 2023 and is anticipated .....
SynopsisEslicarbazepine acetate,an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel. The global Eslicarbazepine Acetate Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030.....
SynopsisEslicarbazepine acetate is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy. The global Eslicarbazepine Acetate API market was valued at US$ million .....
SynopsisIloperidone is an atypical antipsychotic and adrenergic, dopamine, and serotonin (5-HT) receptor antagonist. The global Iloperidone Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % d.....
SynopsisIloperidone is an atypical antipsychotic, a combined dopamine (D2) and serotonin (5HT2) receptor antagonist. Iloperidone targets a selective set of dopamine, serotonin and also norepinephrine receptor subtypes. The global Iloperidone API market was value.....
SynopsisHydrocortisone is a primary glucocorticoid and anti-inflammatory agent The global Hydrocortisone Base Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024.....
SynopsisHydrocortisone is a primary glucocorticoid and anti-inflammatory agent The global Hydrocortisone Base API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-203.....
SynopsisThe global Ivacaftor Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. Ivacaftor is is a CFTR activator. This report aims to provide a comp.....
SynopsisIvacaftor is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (primarily the G551D mutation), who account for 4–5% cases of cystic fibrosis. The global Ivacaftor .....








